Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study is a research paper published in Therapeutic Advances in Neurological Disorders (2023). On theSindex it has a DataRank of 0. It has been cited 5 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Sunovion Pharmaceuticals Inc.
BIAL–Portela & Cª, S.A
FWCI
0.78
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals
sj-docx-1-tan-10.1177_17562864231209240 – Supplemental material for Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study
sj-docx-1-tan-10.1177_17562864231209240 – Supplemental material for Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study